|13.45||-0.3600||-2.61%||Vol 700.88K||1Y Perf 71.98%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||0.31 2.30%|
|Target Price||17.86||Analyst Rating||Strong Buy 1.00|
|Potential %||32.79||Finscreener Ranking||★+ 44.15|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★ 46.56|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★ 38.28|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||92.71||Earnings Rating||Strong Sell|
|Market Cap||857.01M||Earnings Date||15th Aug 2022|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Q04 2020||-0.30||-6.03||-1 910.00|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||15th Aug 2022|
|Estimated EPS Next Report||-0.64|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.24M|
|Avg. Monthly Volume||751.44K|
|Avg. Quarterly Volume||3.00M|
Cogent Biosciences Inc. (NASDAQ: COGT) stock closed at 13.45 per share at the end of the most recent trading day (a -2.61% change compared to the prior day closing price) with a volume of 700.88K shares and market capitalization of 857.01M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 72 people. Cogent Biosciences Inc. CEO is Andrews R. Robbins.
The one-year performance of Cogent Biosciences Inc. stock is 71.98%, while year-to-date (YTD) performance is 56.76%. COGT stock has a five-year performance of %. Its 52-week range is between 3.79 and 14.21, which gives COGT stock a 52-week price range ratio of 92.71%
Cogent Biosciences Inc. currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 6.23, a price-to-sale (PS) ratio of 1 116.28, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -41.03%, a ROC of -73.36% and a ROE of -75.50%. The company’s profit margin is -48.98%, its EBITDA margin is -31 595.20%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Cogent Biosciences Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.64 for the next earnings report. Cogent Biosciences Inc.’s next earnings report date is 15th Aug 2022.
The consensus rating of Wall Street analysts for Cogent Biosciences Inc. is Strong Buy (1), with a target price of $17.86, which is +32.79% compared to the current price. The earnings rating for Cogent Biosciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cogent Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cogent Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 22.09, ATR14 : 1.01, CCI20 : 217.28, Chaikin Money Flow : 0.14, MACD : 0.91, Money Flow Index : 79.10, ROC : 17.57, RSI : 54.70, STOCH (14,3) : 74.83, STOCH RSI : 0.88, UO : 60.05, Williams %R : -25.17), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cogent Biosciences Inc. in the last 12-months were:
Thu, 11 Aug 2022 03:17 GMT Cogent Biosciences (COGT) Receives a Buy from SVB Securities- TipRanks. All rights reserved.
Wed, 16 Mar 2022 10:25 GMT Analysts Top Healthcare Picks: Cogent Biosciences (COGT), BridgeBio Pharma (BBIO)- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.